Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes

References

• Deuschl G, Beghi E, Fazekas F, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):e551–e67. doi:10.1016/S2468-2667(20)30190-0
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. doi:10.1152/physrev.00034.2015
   PubMed Web of Science ®Google Scholar
• De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. 2020;20(6):627–641. doi:10.1080/14737175.2020.1772758
   PubMed Web of Science ®Google Scholar
• Markham A. Erenumab: first global approval. Drugs. 2018;78(11):1157–1161. doi:10.1007/s40265-018-0944-0
   PubMed Web of Science ®Google Scholar
• Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223–231. doi:10.1124/jpet.115.227793
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350. doi:10.1038/s41582-018-0003-1
   PubMed Web of Science ®Google Scholar
• Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs. 2017;31(6):487–501. doi:10.1007/s40259-017-0250-5
   PubMed Web of Science ®Google Scholar
• Barbanti P, Fofi L, Aurilia C, Egeo G. Does the migraine attack start in the cortex and is the cortex critical in the migraine process? Neurol Sci. 2019;40(Suppl 1):31–37. doi:10.1007/s10072-019-03838-y
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR. An update: pathophysiology of migraine. Neurol Clin. 2019;37(4):651–671. doi:10.1016/j.ncl.2019.07.008
   PubMed Web of Science ®Google Scholar
• Stoker K, Baker DE. Erenumab-aooe. Hosp Pharm. 2018;53(6):363–368. doi:10.1177/0018578718797295
   PubMed Web of Science ®Google Scholar
• European Medicine Agencies. Aimovig, INN-erenumab; 2020.
   Google Scholar
• Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, et al. Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia. 2019;39(14):1735–1744. doi:10.1177/0333102419863027
   PubMed Web of Science ®Google Scholar
• Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: a new safety risk for patients treated with erenumab. Headache. 2021;61(1):202–208. doi:10.1111/head.14051
   PubMed Web of Science ®Google Scholar
• Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology. 2020;94(5):e497–e510. doi:10.1212/WNL.0000000000008743
   PubMed Web of Science ®Google Scholar
• González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018;14(1):25–41. doi:10.1080/17425255.2018.1416097
   PubMed Web of Science ®Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382–390. doi:10.1016/S1474-4422(16)00019-3
   PubMed Web of Science ®Google Scholar
• Sakai F, Takeshima T, Tatsuoka Y, et al. A randomized Phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache. 2019;59(10):1731–1742. doi:10.1111/head.13652
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. doi:10.1016/S1474-4422(17)30083-2
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037. doi:10.1177/0333102418759786
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M, Goadsby PJ, Reuter U, et al. Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study. J Neurol Neurosurg Psychiatry. 2021;92(5):466–472. doi:10.1136/jnnp-2020-324396
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2019;39(7):817–826. doi:10.1177/0333102419835459
   PubMed Web of Science ®Google Scholar
• Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611–1621. doi:10.1177/0333102418788347
   PubMed Web of Science ®Google Scholar
• Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92(19):e2250–e60. doi:10.1212/WNL.0000000000007452
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;92(20):e2309–e20. doi:10.1212/WNL.0000000000007497
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020;40(6):543–553. doi:10.1177/0333102420912726
   PubMed Web of Science ®Google Scholar
• Brandes JL, Diener HC, Dolezil D, et al. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. Cephalalgia. 2020;40(1):28–38. doi:10.1177/0333102419894559
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377(22):2123–2132. doi:10.1056/NEJMoa1705848
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287. doi:10.1016/S0140-6736(18)32534-0
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716–1725. doi:10.1111/ene.14715
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology. 2020;95(5):e469–e79. doi:10.1212/WNL.0000000000010019
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Lanteri-Minet M, et al. Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY Study. Neurology. 2021;96(22):e2724–e2735. doi:10.1212/WNL.0000000000012029
   PubMed Web of Science ®Google Scholar
• Pavlovic JM, Paemeleire K, Göbel H, et al. Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain. 2020;21(1):95. doi:10.1186/s10194-020-01167-6
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019;20(1):66. doi:10.1186/s10194-019-1018-8
   PubMed Web of Science ®Google Scholar
• Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine - A randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2021;4:3331024211053571.
   Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. doi:10.1186/s10194-018-0955-y
   PubMed Web of Science ®Google Scholar
• American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
   PubMed Web of Science ®Google Scholar
• Barbanti P, Aurilia C, Egeo G, Fofi L. Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci. 2019;40(Suppl 1):177–179. doi:10.1007/s10072-019-03839-x
   PubMed Web of Science ®Google Scholar
• Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61. doi:10.1186/s10194-020-01127-0
   PubMed Web of Science ®Google Scholar
• Russo A, Silvestro M, Scotto Di Clemente F, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21(1):69. doi:10.1186/s10194-020-01143-0
   PubMed Web of Science ®Google Scholar
• Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32. doi:10.1186/s10194-020-01102-9
   PubMed Web of Science ®Google Scholar
• Scheffler A, Messel O, Wurthmann S, et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020;21(1):84. doi:10.1186/s10194-020-01151-0
   PubMed Web of Science ®Google Scholar
• Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020;40(13):1511–1522. doi:10.1177/0333102420946725
   PubMed Web of Science ®Google Scholar
• Robbins L. Special report: CGRP monoclonal antibodies for chronic migraine. Practical Pain Managemen. 2020;19:45–52.
   Google Scholar
• Ranieri A, Alfieri G, Napolitano M, et al. One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci. 2020;41(Suppl 2):505–506. doi:10.1007/s10072-020-04677-y
   PubMed Web of Science ®Google Scholar
• Pensato U, Favoni V, Pascazio A, et al. Erenumab efficacy in highly resistant chronic migraine: a real-life study. Neurol Sci. 2020;41:457–459. doi:10.1007/s10072-020-04658-1
   PubMed Web of Science ®Google Scholar
• Barbanti P, Aurilia C, Egeo G, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61(2):363–372. doi:10.1111/head.14032
   PubMed Web of Science ®Google Scholar
• Barbanti P, Aurilia C, Cevoli S, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021;61:1351–1363. doi:10.1111/head.14194
   PubMed Web of Science ®Google Scholar
• Pensato U, Baraldi C, Favoni V, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2021;43:1273–1280.
   PubMed Web of Science ®Google Scholar
• Eghtesadi M, Leroux E, Pagé G. Real-life response to erenumab in a therapy-resistant case series of migraine patients from the Province of Québec, Eastern Canada. Clin Drug Investig. 2021;41(8):733–739. doi:10.1007/s40261-021-01059-w
   PubMed Web of Science ®Google Scholar
• Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. 2021;42(10):4193–4202. doi:10.1007/s10072-021-05105-5
   PubMed Web of Science ®Google Scholar
• Storch P, Burow P, Möller B, et al. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice. Acta Neurol Belg. 2021. doi:10.1007/s13760-021-01770-7
   PubMed Web of Science ®Google Scholar
• de Vries Lentsch S, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real-life study. Eur J Neurol. 2021;28(12):4194–4203. doi:10.1111/ene.15075
   PubMed Web of Science ®Google Scholar
• Matteo E, Favoni V, Pascazio A, et al. Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center. Neurol Sci. 2020;41(Suppl 2):483–484. doi:10.1007/s10072-020-04667-0
   PubMed Web of Science ®Google Scholar
• Valle ED, Di Falco M, Mancioli A, Corbetta S, La Spina I. Efficacy and safety of erenumab in the real-life setting of S. Antonio Abate Hospital’s Headache Center (Gallarate). Neurol Sci. 2020;41(Suppl 2):465. doi:10.1007/s10072-020-04752-4
   PubMed Web of Science ®Google Scholar
• Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60(9):2014–2025. doi:10.1111/head.13951
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Kalantzis R, Mecklenburg J, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxina: a Dual-Center Retrospective Observational Study. Front Neurol. 2020;11:417. doi:10.3389/fneur.2020.00417
   PubMed Web of Science ®Google Scholar
• Ornello R, Casalena A, Frattale I, et al. Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain. 2020;21(1):102. doi:10.1186/s10194-020-01171-w
   PubMed Web of Science ®Google Scholar
• Ornello R, Frattale I, Caponnetto V, De Matteis E, Pistoia F, Sacco S. Menstrual headache in women with chronic migraine treated with erenumab: an observational case series. Brain Sci. 2021;11(3):370. doi:10.3390/brainsci11030370
   PubMed Web of Science ®Google Scholar
• De Matteis E, Affaitati G, Frattale I, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci. 2021;42(8):3297–3303. doi:10.1007/s10072-020-05022-z
   PubMed Web of Science ®Google Scholar
• Gantenbein AR, Agosti R, Gobbi C, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - A real-life cohort study. Cephalalgia. 2021;41(11–12):1181–1186. doi:10.1177/03331024211014616
   PubMed Web of Science ®Google Scholar
• de Vries T, MaassenVanDenBrink A. CGRP-targeted antibodies in difficult-to-treat migraine. Nat Rev Neurol. 2019;15(12):688–689. doi:10.1038/s41582-019-0275-0
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Adams AM, Lipton RB, et al. FORWARD Study: evaluating the comparative effectiveness of onabotulinumtoxina and topiramate for headache prevention in adults with chronic migraine. Headache. 2019;59(10):1700–1713. doi:10.1111/head.13653
   PubMed Web of Science ®Google Scholar
• Tiseo C, Ornello R, Pistoia F, Sacco S. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain. 2019;20(1):49. doi:10.1186/s10194-019-1000-5
   PubMed Web of Science ®Google Scholar
• Kokoti L, Drellia K, Papadopoulos D, Mitsikostas DD. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis. J Neurol. 2020;267(4):1158–1170. doi:10.1007/s00415-019-09673-7
   PubMed Web of Science ®Google Scholar
• Ruscheweyh R, Athwal B, Gryglas-Dworak A, et al. Wear-off of onabotulinumtoxina effect over the treatment interval in chronic migraine: a retrospective chart review with analysis of headache diaries. Headache. 2020;60(8):1673–1682. doi:10.1111/head.13925
   PubMed Web of Science ®Google Scholar
• Pak AT, Üstün İ, Sengul Y. Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? Arq Neuropsiquiatr. 2021;79(10):886–890. doi:10.1590/0004-282x-anp-2020-0542
   PubMed Web of Science ®Google Scholar
• Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting calcitonin-gene-related-peptide with the Disease-Modifying Migraine Drugs (DMMDs). J Headache Pain. 2019;20(1):60. doi:10.1186/s10194-019-1009-9
   PubMed Web of Science ®Google Scholar
• Torres-Ferrús M, Ursitti F, Alpuente A, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain. 2020;21(1):42. doi:10.1186/s10194-020-01111-8
   PubMed Web of Science ®Google Scholar
• Mahon R, Lang A, Vo P, et al. Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics. 2021;39(3):357–372. doi:10.1007/s40273-020-00996-2
   PubMed Web of Science ®Google Scholar
• Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P. Cost-effectiveness analysis of erenumab versus OnabotulinumtoxinA for patients with chronic migraine attacks in Greece. Clin Drug Investig. 2019;39(10):979–990. doi:10.1007/s40261-019-00827-z
   PubMed Web of Science ®Google Scholar
• Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38(10):1644–1657. doi:10.1177/0333102418796842
   PubMed Web of Science ®Google Scholar
• Dodick DW, Tepper SJ, Ailani J, et al. Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache. 2021;61(9):1411–1420. doi:10.1111/head.14208
   PubMed Web of Science ®Google Scholar
• Mulder IA, Li M, de Vries T, et al. Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88(4):771–784. doi:10.1002/ana.25831
   PubMed Web of Science ®Google Scholar
• Altamura C, Viticchi G, Fallacara A, et al. Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura. Cephalalgia. 2021;41(1):90–98. doi:10.1177/0333102420956692
   PubMed Web of Science ®Google Scholar
• Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with calcitonin gene-related peptide inhibitor therapy for migraine: a Case Report. J Stroke Cerebrovasc Dis. 2019;28(10):104286. doi:10.1016/j.jstrokecerebrovasdis.2019.07.002
   PubMed Web of Science ®Google Scholar
• Frattale I, Ornello R, Pistoia F, Caponnetto V, Colangeli E, Sacco S. Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab. Intern Emerg Med. 2020;16:227–228. doi:10.1007/s11739-020-02407-y
   PubMed Web of Science ®Google Scholar
• Ornello R, Tiseo C, Frattale I, et al. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain. 2019;20(1):99. doi:10.1186/s10194-019-1054-4
   PubMed Web of Science ®Google Scholar
• Wang X, He Q, Wen D, Ma L, You C. Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons. Neurol Sci. 2021;5:1–8.
   Google Scholar
• Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11(8):e2260. doi:10.1002/brb3.2260
   PubMed Web of Science ®Google Scholar
• Frattale I, Caponnetto V, Casalena A, et al. Association between response to triptans and response to erenumab: real-life data. J Headache Pain. 2021;22(1):1. doi:10.1186/s10194-020-01213-3
   PubMed Web of Science ®Google Scholar
• Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76. doi:10.1186/s10194-020-01130-5
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia;2021. 3331024211046617. doi:10.1177/03331024211046617
   Web of Science ®Google Scholar
• Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006;46(Suppl 4):S182–91. doi:10.1111/j.1526-4610.2006.00602.x
   PubMed Web of Science ®Google Scholar
• May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–464. doi:10.1038/nrneurol.2016.93
   PubMed Web of Science ®Google Scholar
• Ornello R, Sacco S. The paradigm shift in long-term treatments for migraine prevention. Eur J Neurol. 2021;28(5):1439–1440. doi:10.1111/ene.14768
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Vecchio E, Quitadamo SG, et al. Pain-related brain connectivity changes in migraine: a narrative review and proof of concept about possible novel treatments interference. Brain Sci. 2021;11(2):234. doi:10.3390/brainsci11020234
   PubMed Web of Science ®Google Scholar
• Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020;94(20):e2121–e5. doi:10.1212/WNL.0000000000008944
   PubMed Web of Science ®Google Scholar
• Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734–1742. doi:10.1111/head.13930
   PubMed Web of Science ®Google Scholar
• Jakate A, Blumenfeld AM, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642–652. doi:10.1111/head.14095
   PubMed Web of Science ®Google Scholar
• Overeem LH, Peikert A, Hofacker MD, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia;2021. 3331024211048765. doi:10.1177/03331024211048765
   Web of Science ®Google Scholar
• Ziegeler C, May A. Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache. 2020;60(2):469–470. doi:10.1111/head.13729
   PubMed Web of Science ®Google Scholar
• Briceño-Casado MDP, Gil-Sierra MD, De-la-calle-riaguas B. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm. 2021;ejhpharm-2021-002946. doi:10.1136/ejhpharm-2021-002946
   PubMedGoogle Scholar
• Patier Ruiz I, Sánchez-Rubio Ferrández J, Cárcamo Fonfría A, Molina García T. Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a Case Series. Eur Neurol. 2021;1–4. doi:10.1159/000518899
   PubMed Web of Science ®Google Scholar
• Sacco S, Russo A, Geppetti P, et al. What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Rev Neurother. 2020;20(12):1275–1286. doi:10.1080/14737175.2020.1825077
   PubMed Web of Science ®Google Scholar
• Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and onabotulinumtoxina combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2021;35(1):1–6. doi:10.1080/15360288.2020.1829249
   PubMed Web of Science ®Google Scholar
• Silvestro M, Tessitore A, Scotto Di Clemente F, Battista G, Tedeschi G, Russo A. Additive interaction between Onabotulinumtoxin-A and erenumab in patients with refractory migraine. Front Neurol. 2021;12:656294. doi:10.3389/fneur.2021.656294
   PubMed Web of Science ®Google Scholar
• Toni T, Tamanaha R, Newman B, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci. 2021;42(12):5373–5376. doi:10.1007/s10072-021-05547-x
   PubMed Web of Science ®Google Scholar
• Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action - review of a selective 5-HT(1F) agonist. J Headache Pain. 2020;21(1):71. doi:10.1186/s10194-020-01132-3
   PubMed Web of Science ®Google Scholar
• NICE guidelines.Management of migraine (with or without aura); 2021; https://www.nice.org.uk/guidance/conditions-and-diseases/neurological-conditions/headaches.
   Google Scholar
• Schwedt T, Reuter U, Tepper S, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19(1):92. doi:10.1186/s10194-018-0923-6
   PubMed Web of Science ®Google Scholar
• Ziegeler C, Mehnert J, Asmussen K, May A. Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology. 2020;95(20):e2794–e802. doi:10.1212/WNL.0000000000010740
   PubMed Web of Science ®Google Scholar